Nothing Special   »   [go: up one dir, main page]

MX2019004734A - Formas polimorficas de benzoato de sodio y usos de las mismas. - Google Patents

Formas polimorficas de benzoato de sodio y usos de las mismas.

Info

Publication number
MX2019004734A
MX2019004734A MX2019004734A MX2019004734A MX2019004734A MX 2019004734 A MX2019004734 A MX 2019004734A MX 2019004734 A MX2019004734 A MX 2019004734A MX 2019004734 A MX2019004734 A MX 2019004734A MX 2019004734 A MX2019004734 A MX 2019004734A
Authority
MX
Mexico
Prior art keywords
sodium benzoate
polymorphic forms
degrees
approximately
disclosed
Prior art date
Application number
MX2019004734A
Other languages
English (en)
Inventor
Emil Tsai Guochuan
Cheng Wang Ching-
Lan HSIEH Tien-
Original Assignee
Syneurx Int Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syneurx Int Taiwan Corp filed Critical Syneurx Int Taiwan Corp
Publication of MX2019004734A publication Critical patent/MX2019004734A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente divulgacion proporciona formas polimorficas de benzoato de sodio con un patron de difraccion de rayos X que comprende picos caracteristicos a un angulo de reflexion 2? de aproximadamente 5.9, 30.2 y 31.2 grados; o un patron de difraccion de rayos X que comprende picos caracteristicos a un angulo de reflexion 2? de aproximadamente 3.7, 5.9 y 26.6 grados; en la presente tambien se proporcionan metodos para preparar las formas polimorficas de benzoato de sodio y usos de las mismas para tratar y/o reducir el riesgo de un trastorno neuropsiquiatrico (por ejemplo, esquizofrenia, trastornos psicoticos, trastornos depresivos o enfermedad de Alzheimer).
MX2019004734A 2016-10-24 2017-10-24 Formas polimorficas de benzoato de sodio y usos de las mismas. MX2019004734A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662412160P 2016-10-24 2016-10-24
US15/452,137 US10336679B2 (en) 2016-10-24 2017-03-07 Polymorphic forms of sodium benzoate and uses thereof
PCT/CN2017/107436 WO2018077157A1 (en) 2016-10-24 2017-10-24 Polymorphic forms of sodium benzoate and uses thereof

Publications (1)

Publication Number Publication Date
MX2019004734A true MX2019004734A (es) 2019-09-26

Family

ID=61970963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004734A MX2019004734A (es) 2016-10-24 2017-10-24 Formas polimorficas de benzoato de sodio y usos de las mismas.

Country Status (10)

Country Link
US (1) US10336679B2 (es)
EP (1) EP3529229B1 (es)
JP (1) JP7141124B2 (es)
KR (1) KR102511444B1 (es)
CN (1) CN110167909B (es)
CA (1) CA3041389A1 (es)
IL (2) IL266210B (es)
MX (1) MX2019004734A (es)
TW (5) TWI781723B (es)
WO (1) WO2018077157A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3027297A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
TW202206061A (zh) * 2017-11-22 2022-02-16 林潔欣 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途
CN118955352A (zh) 2017-12-05 2024-11-15 赛诺维信制药公司 晶体形式及其制备方法
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
US20210186937A1 (en) * 2018-05-22 2021-06-24 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
US20220304962A1 (en) * 2019-04-24 2022-09-29 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用
MY197760A (en) 2020-06-01 2023-07-13 Celagenex Res India Pvt Ltd Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498989A (en) 1969-04-16 1970-03-03 American Home Prod Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en) 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4041174A (en) 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5198217A (en) * 1991-09-24 1993-03-30 Choice Pharmaceuticals Topical demulcent for viral and inflammatory diseases of the skin
FR2700117B1 (fr) 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) 1993-11-26 1995-06-01 Karla Dr Lehmann Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6255089B1 (en) * 1997-02-27 2001-07-03 Albany Medical College Constitutively activated serotonin receptors
IN191496B (es) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
AU4517201A (en) * 1999-12-08 2001-06-18 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
MXPA03006321A (es) 2001-01-16 2003-10-06 Genset Sa Tratamiento de trastornos del sistema nervioso central usando antagonistas de d-aminoacido oxidasa y d-aspartato oxidasa.
US20030185754A1 (en) 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20040087658A1 (en) 2002-10-24 2004-05-06 Hans-Joerg Moebius Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
CA2527284A1 (en) 2003-06-02 2005-01-06 Laurent Lecanu Methods and compositions for modulating serum cortisol levels
EP1711478A2 (en) 2003-12-29 2006-10-18 Sepracor Inc. Benzo [d]isoxazol-3-ol daao inhibitors
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
EP1742535A4 (en) 2004-05-06 2008-10-15 Cydex Pharmaceuticals Inc MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006129160A2 (en) 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
US20110045065A1 (en) 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0603181D0 (en) 2006-02-17 2006-03-29 Merck Sharp & Dohme Treatment of neurodegenerative and psychiatric diseases
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
WO2008034087A2 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
US8263652B2 (en) 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
DK3006024T3 (da) 2009-01-20 2019-06-03 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Benzoesyre eller salte deraf til forstærkning af aktiviteten af et neurofarmaceutisk lægemiddel
JP2016517866A (ja) * 2014-03-24 2016-06-20 カオシュン・チャン・グン・メモリアル・ホスピタル 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用
US10064833B2 (en) 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
US10098861B1 (en) * 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Also Published As

Publication number Publication date
TWI784662B (zh) 2022-11-21
TW202146369A (zh) 2021-12-16
RU2019113765A3 (es) 2021-06-25
JP2019532968A (ja) 2019-11-14
EP3529229A1 (en) 2019-08-28
KR102511444B1 (ko) 2023-03-16
TWI739938B (zh) 2021-09-21
TWI781723B (zh) 2022-10-21
TW202144317A (zh) 2021-12-01
TW201829365A (zh) 2018-08-16
RU2019113765A (ru) 2020-11-24
TWI803935B (zh) 2023-06-01
IL266210A (en) 2019-06-30
TWI784663B (zh) 2022-11-21
EP3529229A4 (en) 2020-09-30
TW202144316A (zh) 2021-12-01
CN110167909A (zh) 2019-08-23
JP7141124B2 (ja) 2022-09-22
US20180111891A1 (en) 2018-04-26
IL292244A (en) 2022-06-01
US20180346400A9 (en) 2018-12-06
CN110167909B (zh) 2023-09-19
WO2018077157A1 (en) 2018-05-03
TW202144315A (zh) 2021-12-01
KR20190077003A (ko) 2019-07-02
IL266210B (en) 2022-06-01
EP3529229B1 (en) 2024-04-17
CA3041389A1 (en) 2018-05-03
US10336679B2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
MX2019004734A (es) Formas polimorficas de benzoato de sodio y usos de las mismas.
IL279133A (en) Binder-drug conjugates activated in the microenvironment and their related uses
IL268469B (en) 2-Heteroaryl-3-oxo-3,2-dihydropyridazine-4-carboxamides for cancer treatment
WO2016179558A8 (en) K-ras modulators
SG11202104356VA (en) Bt1718 for use in treating cancer
MX2022008100A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
SG10201809411PA (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
EP3426777A4 (en) COMBINATION VECTORS AND METHOD FOR THE TREATMENT OF CANCER
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
PH12017500881B1 (en) Aurora a kinase inhibitor
BR112017022022A2 (pt) arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
ZA201804361B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL259510A (en) 1, 3, 4-thiadiazole compounds and their use for cancer treatment
IL258644A (en) 4,3,1-thiadiazole compounds and their use for cancer treatment
IL269121A (en) Usl-311 for use in the treatment of cancer
EP3674398A4 (en) ECHOVIRUS FOR TUMOR TREATMENT
WO2015134603A3 (en) Methods for treating cancer
HK1251476A1 (zh) 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽
IL282692A (en) Compounds derived from madrasin, a preparation and their uses for the treatment of cancer
IL277038A (en) Bexarotane derivatives and their use for cancer treatment
IL288591A (en) Methods and uses for cancer treatment
PT3813832T (pt) Compostos para utilização na prevenção ou tratamento de cancro
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
AU2017902125A0 (en) "Agents for cancer therapy or prophylaxis and uses therefor"